拉夫利珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 补体成分5 |
| 临床资料 | |
| 读音 | rav" ue liz' ue mab |
| 商品名 | Ultomiris |
| 其他名称 | ALXN1210, ravulizumab-cwvz |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619014 |
| 核准状况 | |
| 怀孕分级 |
|
| 给药途径 | 静脉注射 |
| 药物类别 | 补体系统抑制剂 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 药物动力学数据 | |
| 药物代谢 | various proteases |
| 识别信息 | |
| CAS号 | 1803171-55-2 |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6430H9888N1696O2028S48 |
| 摩尔质量 | 144,938.56 g·mol−1 |
拉夫利珠单抗（INN：Ravulizumab）用于治疗阵发性夜间血红素尿症和非典型溶血尿毒症综合征[8]。透过静脉缓慢注射[9]。
常见副作用包括上呼吸道感染、腹泻、发烧、恶心和头痛[10] [8]。其他副作用包括可能脑膜炎双球菌感染[10]。虽然孕期使用没有明显危害，但研究仍不充分[11]。它是一种单克隆抗体，可与补体成分5（C5）结合并阻断其活性[10]。
拉夫利珠单抗于2018年及2019年在美国及欧洲取得医疗使用许可[9] [10]。
参考文献
[编辑]- ^ Ultomiris. Therapeutic Goods Administration (TGA). 26 May 2022 [9 March 2024]. （原始内容存档于2025-01-16）.
- ^ Ultomiris Product information. Health Canada. [29 May 2022]. （原始内容存档于2022-05-30）.
- ^ Summary Basis of Decision (SBD) for Ultomiris. Health Canada. 23 October 2014 [29 May 2022]. （原始内容存档于2022-05-31）.
- ^ Regulatory Decision Summary for Ultomiris. Drug and Health Products Portal. 6 January 2023 [1 April 2024]. （原始内容存档于2025-01-14）.
- ^ Ultomiris 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC). (emc). [12 October 2020]. （原始内容存档于18 October 2020）.
- ^ Ultomiris- ravulizumab solution, concentrate. DailyMed. 20 March 2020 [1 May 2020]. （原始内容存档于2020-09-23）.
- ^ Ultomiris EPAR. European Medicines Agency (EMA). 24 April 2019 [1 May 2020]. （原始内容存档于2020-05-08）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 8.0 8.1 DailyMed - ULTOMIRIS- ravulizumab solution, concentrate. dailymed.nlm.nih.gov. [16 October 2021]. （原始内容存档于23 September 2020）. 互联网档案馆的存档，存档日期23 September 2020.
- ^ 9.0 9.1 Ravulizumab-cwvz Monograph for Professionals. Drugs.com. [16 October 2021]. （原始内容存档于31 March 2024） （英语）. 互联网档案馆的存档，存档日期31 March 2024.
- ^ 10.0 10.1 10.2 10.3 Ultomiris EPAR. European Medicines Agency (EMA). 24 April 2019 [1 May 2020]. （原始内容存档于8 May 2020）. 互联网档案馆的存档，存档日期8 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Ravulizumab (Ultomiris) Use During Pregnancy. Drugs.com. [16 October 2021]. （原始内容存档于29 October 2020） （英语）. 互联网档案馆的存档，存档日期29 October 2020.
延伸阅读
[编辑]- Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019, 10: 2040620719874728. PMC 6737867
. PMID 31534662. doi:10.1177/2040620719874728.
| 产品 | |
|---|---|
| 前身和收购 | |
| 人物 | |
